KYNTRA BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
KYNTRA BIO, INC. (KYNB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $15.14 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-16
- KYNTRA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $15.14, a 65.14% decline from fiscal 2024.
- KYNTRA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $43.43, a 497.39% increase from fiscal 2023.
- KYNTRA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $7.27, a 50.61% decline from fiscal 2022.
- KYNTRA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $14.72, a 58.63% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $15.14 10-K · filed 2026-03-16 | |
| 2024-12-31 | $43.43 10-K · filed 2026-03-16 | $1.74 10-K · filed 2025-03-17 |
| 2023-12-31 | $7.27 10-K · filed 2025-03-17 | |
| 2022-12-31 | $14.72 10-K · filed 2024-02-26 | |
| 2021-12-31 | $35.58 10-K · filed 2024-02-26 | |
| 2020-12-31 | $31.55 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |